{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T16:40:03Z","timestamp":1789749603899,"version":"4.0.1"},"reference-count":119,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.drudis.2026.104727","type":"journal-article","created":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T16:44:25Z","timestamp":1782492265000},"page":"104727","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Targeting the GLP-1 receptor pathways for dual management of obesity and depression"],"prefix":"10.1016","volume":"31","author":[{"given":"Ruchi","family":"Keswani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8696-3462","authenticated-orcid":false,"given":"Shvetank","family":"Bhatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drudis.2026.104727_b0005","first-page":"5917","article-title":"Shared biological mechanisms of depression and obesity: focus on adipokines and lipokines","volume":"15","author":"Fu","year":"2023","journal-title":"Aging"},{"key":"10.1016\/j.drudis.2026.104727_b0010","unstructured":"Depressive disorder (depression). Accessed March 18, 2026. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/depression."},{"key":"10.1016\/j.drudis.2026.104727_b0015","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/S0140-6736(23)02750-2","article-title":"Worldwide trends in underweight and obesity from 1990 to 2022: a pooled analysis of 3663 population-representative studies with 222 million children, adolescents, and adults","volume":"403","author":"Phelps","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.drudis.2026.104727_b0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2025.104509","article-title":"Exploring the role of adipocytokines in obesity associated depression","volume":"30","author":"Keswani","year":"2025","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.drudis.2026.104727_b0025","first-page":"1","article-title":"Depression and obesity","volume":"14","author":"Gerardo","year":"2025","journal-title":"Curr Obesity Rep"},{"key":"10.1016\/j.drudis.2026.104727_b0030","article-title":"Depression and metabolic syndrome: a narrative review","volume":"14","author":"Al-Khatib","year":"2022","journal-title":"Cureus"},{"key":"10.1016\/j.drudis.2026.104727_b0035","doi-asserted-by":"crossref","first-page":"140","DOI":"10.9734\/indj\/2025\/v22i5522","article-title":"The microbiota-gut-brain axis in neuropsychiatric and neurodegenerative disorders: convergent mechanisms and translational prospects","volume":"22","author":"Adom","year":"2025","journal-title":"Int Neuropsychiatr Dis J"},{"key":"10.1016\/j.drudis.2026.104727_b0040","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1007\/s11064-023-04084-7","article-title":"Gut-brain axis modulation of metabolic disorders: exploring the intertwined neurohumoral pathways and therapeutic prospects","volume":"49","author":"Bhalla","year":"2024","journal-title":"Neurochem Res"},{"key":"10.1016\/j.drudis.2026.104727_b0045","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1176\/appi.neuropsych.20230226","article-title":"Glucagon-like peptide 1: an introduction and possible implications for neuropsychiatry","volume":"36","author":"L\u00f3pez-Ojeda","year":"2024","journal-title":"J Neuropsych Clin Neurosci"},{"key":"10.1016\/j.drudis.2026.104727_b0050","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.1046130","article-title":"Semaglutide ameliorates metabolism and hepatic outcomes in an NAFLD mouse model","volume":"13","author":"Niu","year":"2022","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.drudis.2026.104727_b0055","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1002\/oby.70122","article-title":"Psychiatric safety of tirzepatide in people with obesity and no known major psychopathology: a post hoc analysis of SURMOUNT","volume":"34","author":"Wadden","year":"2026","journal-title":"Obesity"},{"key":"10.1016\/j.drudis.2026.104727_b0060","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bbi.2017.08.026","article-title":"Effects of obesity on depression: a role for inflammation and the gut microbiota","volume":"69","author":"Schachter","year":"2018","journal-title":"Brain Behav Immun"},{"key":"10.1016\/j.drudis.2026.104727_b0065","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1606375","article-title":"Cytokine concentration in peripheral blood of patients with childhood obesity","volume":"16","author":"Mai","year":"2025","journal-title":"Front Immunol"},{"key":"10.1016\/j.drudis.2026.104727_b0070","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/S0899-9007(01)00507-X","article-title":"Anorectic effects of circulating cytokines: role of the vascular blood-brain barrier","volume":"17","author":"Banks","year":"2001","journal-title":"Nutrition"},{"key":"10.1016\/j.drudis.2026.104727_b0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2023.103697","article-title":"Targeting inflammatory pathways for treatment of the major depressive disorder","volume":"28","author":"Patil","year":"2023","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.drudis.2026.104727_b0080","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2024.1407529","article-title":"Efficacy and acceptability of anti-inflammatory agents in major depressive disorder: a systematic review and meta-analysis","volume":"15","author":"Du","year":"2024","journal-title":"Front Psychiatry"},{"key":"10.1016\/j.drudis.2026.104727_b0085","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.jad.2025.02.053","article-title":"Exploring the potential antidepressant mechanisms of ibuprofen and celecoxib based on network pharmacology and molecular docking","volume":"377","author":"Abbasi","year":"2025","journal-title":"J Affect Disord"},{"key":"10.1016\/j.drudis.2026.104727_b0090","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.5937\/jomb0-59562","article-title":"Oxidative stress in adolescents with overweight\/obesity","volume":"44","author":"Bozovic","year":"2026","journal-title":"J Med Biochem"},{"key":"10.1016\/j.drudis.2026.104727_b0095","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1007\/s12035-026-05715-0","article-title":"Oxidative stress in treatment-resistant and refractory depression: a hidden therapeutic target?","volume":"63","author":"Winczewska","year":"2026","journal-title":"Mol Neurobiol"},{"key":"10.1016\/j.drudis.2026.104727_b0100","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.lfs.2017.11.019","article-title":"Mitochondrial dysfunction in obesity","volume":"192","author":"de Mello","year":"2018","journal-title":"Life Sci"},{"key":"10.1016\/j.drudis.2026.104727_b0105","doi-asserted-by":"crossref","first-page":"117","DOI":"10.3390\/antiox13010117","article-title":"Oxidative stress, inflammation, and mitochondrial dysfunction: a link between obesity and atrial fibrillation","volume":"13","author":"Balan","year":"2024","journal-title":"Antioxidants"},{"key":"10.1016\/j.drudis.2026.104727_b0110","doi-asserted-by":"crossref","first-page":"117","DOI":"10.3390\/biom16010117","article-title":"Mitochondrial dysfunction: the cellular bridge from emotional stress to disease onset: a narrative review","volume":"16","author":"Krause","year":"2026","journal-title":"Biomolecules"},{"key":"10.1016\/j.drudis.2026.104727_b0115","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S2468-1253(17)30147-4","article-title":"The microbiota\u2013gut\u2013brain axis in obesity","volume":"2","author":"Torres-Fuentes","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.drudis.2026.104727_b0120","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1007\/s00018-025-06022-y","article-title":"Microbes, mood, and metabolism\/obesity: pharmacological insights into the gut-obesity-depression triad","volume":"83","author":"Yadav","year":"2026","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.drudis.2026.104727_b0125","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s43556-025-00307-1","article-title":"Microbiota\u2013gut\u2013brain axis in neurodegenerative diseases: molecular mechanisms and therapeutic targets","volume":"6","author":"Chen","year":"2025","journal-title":"Mol Biomed"},{"key":"10.1016\/j.drudis.2026.104727_b0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2024.103921","article-title":"Potential of postbiotics for the treatment of metabolic disorders","volume":"29","author":"Mishra","year":"2024","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.drudis.2026.104727_b0135","doi-asserted-by":"crossref","DOI":"10.1080\/19490976.2025.2551879","article-title":"Early-life gut microbiome maturity regulates blood\u2013brain barrier and cognitive development","volume":"17","author":"Zemmel","year":"2025","journal-title":"Gut Microbes"},{"key":"10.1016\/j.drudis.2026.104727_b0140","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2022.900652","article-title":"Therapeutic effect of fecal microbiota transplantation on chronic unpredictable mild stress-induced depression","volume":"12","author":"Cai","year":"2022","journal-title":"Front Cell Infect Microbiol"},{"key":"10.1016\/j.drudis.2026.104727_b0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.neubiorev.2023.105316","article-title":"Systematic review and meta-analysis of the effect of fecal microbiota transplantation on behavior in animals","volume":"153","author":"Keubler","year":"2023","journal-title":"Neurosci Biobehav Rev"},{"key":"10.1016\/j.drudis.2026.104727_b0150","doi-asserted-by":"crossref","first-page":"276","DOI":"10.2174\/1871527321666220329140804","article-title":"Role of brain-gut-microbiota axis in depression: emerging therapeutic avenues","volume":"22","author":"Bhatt","year":"2023","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"10.1016\/j.drudis.2026.104727_b0155","doi-asserted-by":"crossref","first-page":"3351","DOI":"10.2147\/IDR.S254403","article-title":"The impact of gut microbiota disorders on the blood\u2013brain barrier","volume":"13","author":"Tang","year":"2020","journal-title":"Infect Drug Resist"},{"key":"10.1016\/j.drudis.2026.104727_b0160","doi-asserted-by":"crossref","unstructured":"Khatun A, Patra S, Ghosh K, Pradhan S, Chakrabarti S. Diet-induced overweight conditions: effect on brain structure, cognitive function, and neurogenesis. Obesity \u2013 Recent Insights Therapeutic Options. Published online. https:\/\/doi.org\/10.5772\/intechopen.110610.","DOI":"10.5772\/intechopen.110610"},{"key":"10.1016\/j.drudis.2026.104727_b0165","doi-asserted-by":"crossref","DOI":"10.3389\/fncel.2023.1294420","article-title":"The complex relationship between obesity and neurodegenerative diseases: an updated review","volume":"17","author":"Neto","year":"2023","journal-title":"Front Cell Neurosci"},{"key":"10.1016\/j.drudis.2026.104727_b0170","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.3390\/ijms19082281","article-title":"Association between obesity and circulating brain-derived neurotrophic factor (BDNF) levels: systematic review of literature and meta-analysis","volume":"19","author":"Sandrini","year":"2018","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.drudis.2026.104727_b0175","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.ibneur.2022.09.001","article-title":"Neural plasticity and depression treatment","volume":"14","author":"Wang","year":"2023","journal-title":"IBRO Neurosci Rep"},{"key":"10.1016\/j.drudis.2026.104727_b0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.pnpbp.2025.111470","article-title":"Whole blood BDNF is lower in patients with depression and unchanged by escitalopram in patients and healthy controls","volume":"141","author":"Navarro","year":"2025","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.drudis.2026.104727_b0185","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/s41392-024-01931-z","article-title":"Glucagon-like peptide-1 receptor: mechanisms and advances in therapy","volume":"9","author":"Zheng","year":"2024","journal-title":"Signal Transduct Target Therapy"},{"key":"10.1016\/j.drudis.2026.104727_b0190","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1124\/pr.115.011395","article-title":"Glucagon-like peptide-1 and its class B G protein\u2013coupled receptors: a long march to therapeutic successes","volume":"68","author":"de Graaf","year":"2016","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.drudis.2026.104727_b0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2024.116119","article-title":"The role of G protein-coupled receptor kinases in GLP-1R \u03b2-arrestin recruitment and internalisation","volume":"222","author":"McNeill","year":"2024","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.drudis.2026.104727_b0200","doi-asserted-by":"crossref","first-page":"7239","DOI":"10.3390\/ijms26157239","article-title":"Glucagon-like peptide-1 receptor (GLP-1R) signaling: making the case for a functionally Gs protein-selective GPCR","volume":"26","author":"Lymperopoulos","year":"2025","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.drudis.2026.104727_b0205","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/jdi.13136","article-title":"New concept of the glucagon-like peptide-1 signaling pathway on pancreatic insulin secretion","volume":"11","author":"Kaku","year":"2020","journal-title":"J Diabetes Investig"},{"key":"10.1016\/j.drudis.2026.104727_b0210","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.neuint.2019.04.010","article-title":"GLP-1: molecular mechanisms and outcomes of a complex signaling system","volume":"128","author":"Smith","year":"2019","journal-title":"Neurochem Int"},{"key":"10.1016\/j.drudis.2026.104727_b0215","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.721135","article-title":"GLP-1 receptor agonists: beyond their pancreatic effects","volume":"12","author":"Zhao","year":"2021","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.drudis.2026.104727_b0220","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2024.107300","article-title":"PI3K\/AKT signaling pathway: molecular mechanisms and therapeutic potential in depression","volume":"206","author":"Guo","year":"2024","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.drudis.2026.104727_b0225","doi-asserted-by":"crossref","DOI":"10.3389\/fnmol.2022.831151","article-title":"The cAMP response element- binding protein\/brain-derived neurotrophic factor pathway in anterior cingulate cortex regulates neuropathic pain and anxiodepression like behaviors in rats","volume":"15","author":"Wen","year":"2022","journal-title":"Front Mol Neurosci"},{"key":"10.1016\/j.drudis.2026.104727_b0230","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.3389\/fphar.2020.01270","article-title":"Alleviation of depression by glucagon-like peptide 1 through the regulation of neuroinflammation, neurotransmitters, neurogenesis, and synaptic function","volume":"11","author":"Kim","year":"2020","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.drudis.2026.104727_b0235","doi-asserted-by":"crossref","first-page":"333","DOI":"10.4093\/dmj.2025.0106","article-title":"Glucagon-like peptide-1 and hypothalamic regulation of satiation: cognitive and neural insights from human and animal studies","volume":"49","author":"Park","year":"2025","journal-title":"Diabetes Metab J"},{"key":"10.1016\/j.drudis.2026.104727_b0240","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.amjmed.2025.01.021","article-title":"Mechanisms of GLP-1 receptor agonist-induced weight loss: a review of central and peripheral pathways in appetite and energy regulation","volume":"138","author":"Moiz","year":"2025","journal-title":"Am J Med"},{"key":"10.1016\/j.drudis.2026.104727_b0245","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102782","article-title":"GLP-1 single, dual, and triple receptor agonists for treating type 2 diabetes and obesity: a narrative review","volume":"75","author":"Alfaris","year":"2024","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.drudis.2026.104727_b0250","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.3390\/biomedicines13071610","article-title":"GLP-1 and its role in glycogen production: a narrative review","volume":"13","author":"Lotosky","year":"2025","journal-title":"Biomedicines"},{"key":"10.1016\/j.drudis.2026.104727_b0255","doi-asserted-by":"crossref","DOI":"10.1172\/JCI194744","article-title":"GLP-1 physiology and pharmacology along the gut-brain axis","volume":"136","author":"Beutler","year":"2026","journal-title":"J Clin Invest"},{"key":"10.1016\/j.drudis.2026.104727_b0260","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuint.2020.104772","article-title":"Glucagon-like peptide-1 receptor regulation of basal dopamine transporter activity is species-dependent","volume":"138","author":"Jensen","year":"2020","journal-title":"Neurochem Int"},{"key":"10.1016\/j.drudis.2026.104727_b0265","doi-asserted-by":"crossref","DOI":"10.1210\/endocr\/bqaa093","article-title":"A role for GLP-1 in treating hyperphagia and obesity","volume":"161","author":"Grill","year":"2020","journal-title":"Endocrinology"},{"key":"10.1016\/j.drudis.2026.104727_b0270","doi-asserted-by":"crossref","DOI":"10.1177\/20420188231222367","article-title":"Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications","volume":"15","author":"Alharbi","year":"2024","journal-title":"Ther Adv Endocrinol Metab"},{"key":"10.1016\/j.drudis.2026.104727_b0275","doi-asserted-by":"crossref","DOI":"10.1002\/jcsm.13677","article-title":"The effects of glucagon\u2010like peptide\u20101 receptor agonists on mitochondrial function within skeletal muscle: a systematic review","volume":"16","author":"Old","year":"2025","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.drudis.2026.104727_b0280","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1515\/med-2020-0212","article-title":"Effect of glucagon-like peptide-1 receptor agonists on adipokine level of nonalcoholic fatty liver disease in rats fed high-fat diet","volume":"15","author":"Jin","year":"2020","journal-title":"Open Med"},{"key":"10.1016\/j.drudis.2026.104727_b0285","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.116763","article-title":"Potent synergistic effects of dulaglutide and food restriction in prevention of olanzapine-induced metabolic adverse effects in a rodent model","volume":"176","author":"Horska","year":"2024","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.drudis.2026.104727_b0290","doi-asserted-by":"crossref","DOI":"10.1016\/j.obpill.2025.100181","article-title":"Nutritional priorities to support GLP-1 therapy for obesity: a joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and the Obesity Society","volume":"15","author":"Mozaffarian","year":"2025","journal-title":"Obesity Pillars"},{"key":"10.1016\/j.drudis.2026.104727_b0295","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/s12902-025-01952-x","article-title":"Effect of intermittent fasting on obesity and metabolic indices in patients with metabolic syndrome: a systematic review and meta analysis","volume":"25","author":"Zhang","year":"2025","journal-title":"BMC Endocr Disord"},{"key":"10.1016\/j.drudis.2026.104727_b0300","doi-asserted-by":"crossref","first-page":"3079","DOI":"10.3390\/biomedicines13123079","article-title":"Added value to GLP-1 receptor agonist: intermittent fasting and lifestyle modification to improve therapeutic effects and outcomes","volume":"13","author":"Cozma","year":"2025","journal-title":"Biomedicines"},{"key":"10.1016\/j.drudis.2026.104727_b0305","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.3390\/nu15122749","article-title":"Global impacts of western diet and its effects on metabolism and health: a narrative review","volume":"15","author":"Clemente-Su\u00e1rez","year":"2023","journal-title":"Nutrients"},{"key":"10.1016\/j.drudis.2026.104727_b0310","doi-asserted-by":"crossref","first-page":"3164","DOI":"10.3390\/cells10113164","article-title":"High-fat, western-style diet, systemic inflammation, and gut microbiota: a narrative review","volume":"10","author":"Malesza","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.drudis.2026.104727_b0315","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/dom.70198","article-title":"Psychiatric effects of GLP\u20101 receptor agonists: a systematic review of emerging evidence","volume":"28","author":"Sa","year":"2025","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.drudis.2026.104727_b0320","doi-asserted-by":"crossref","first-page":"9583","DOI":"10.3390\/ijms23179583","article-title":"Anti-inflammatory effects of GLP-1 receptor activation in the brain in neurodegenerative diseases","volume":"23","author":"Diz-Chaves","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.drudis.2026.104727_b0325","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1139\/cjpp-2025-0148","article-title":"Anti-inflammatory properties of GLP-1 receptor agonists and other ancillary benefits from a pharmacological perspective","volume":"103","author":"Ros-Madrid","year":"2025","journal-title":"Can J Physiol Pharmacol"},{"key":"10.1016\/j.drudis.2026.104727_b0330","doi-asserted-by":"crossref","first-page":"26","DOI":"10.3390\/ijms19010026","article-title":"Effects of glucagon-like peptide-1 on oxidative stress and Nrf2 signaling","volume":"19","author":"Oh","year":"2017","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.drudis.2026.104727_b0335","article-title":"Molecular evidence associating GLP-1 receptor agonists and brain-derived neurotrophic factors in neurodegenerative and psychiatric disorders: a systematic review","volume":"117","author":"Abdelwahed","year":"2026","journal-title":"Asian J Psychiatr"},{"key":"10.1016\/j.drudis.2026.104727_b0340","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2025.108036","article-title":"Psychotropic effects of GLP-1R agonists","volume":"222","author":"Bucciarelli","year":"2025","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.drudis.2026.104727_b0345","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.3390\/life15091422","article-title":"GLP-1 receptor agonists in mood disorders: a psychiatric perspective","volume":"15","author":"Carmellini","year":"2025","journal-title":"Life"},{"key":"10.1016\/j.drudis.2026.104727_b0350","doi-asserted-by":"crossref","first-page":"7551","DOI":"10.3390\/ijms21207551","article-title":"Gut\u2013brain axis: role of gut microbiota on neurological disorders and how probiotics\/prebiotics beneficially modulate microbial and immune pathways to improve brain functions","volume":"21","author":"Suganya","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.drudis.2026.104727_b0355","doi-asserted-by":"crossref","DOI":"10.1080\/23312025.2016.1229086","article-title":"The physiological role of the brain GLP-1 system in stress","volume":"2","author":"Holt","year":"2016","journal-title":"Cogent Biol"},{"key":"10.1016\/j.drudis.2026.104727_b0360","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2025.1708565","article-title":"GLP-1 receptor agonists in Alzheimer\u2019s and Parkinson\u2019s disease: endocrine pathways, clinical evidence, and future directions","volume":"16","author":"Gandhi","year":"2025","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.drudis.2026.104727_b0365","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.neuropharm.2017.11.015","article-title":"Glucagon-like Peptide-1 (GLP-1) and neurotransmitters signaling in epilepsy: an insight review","volume":"136","author":"Koshal","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.drudis.2026.104727_b0370","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106550","article-title":"Glucagon-like peptide-1 (GLP-1) receptor agonists and neuroinflammation: implications for neurodegenerative disease treatment","volume":"186","author":"Kopp","year":"2022","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.drudis.2026.104727_b0375","doi-asserted-by":"crossref","first-page":"2801","DOI":"10.1007\/s00213-025-06834-7","article-title":"Liraglutide improves depressive and cognitive deficits in a high-fat diet rat model of obesity: the role of hippocampal autophagy and the PI3K\/Akt\/mTOR pathway","volume":"242","author":"Magdy","year":"2025","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.drudis.2026.104727_b0380","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1530\/JOE-16-0478","article-title":"The effects of liraglutide in mice with diet-induced obesity studied by metabolomics","volume":"233","author":"Bug\u00e1\u0148ov\u00e1","year":"2017","journal-title":"J Endocrinol"},{"key":"10.1016\/j.drudis.2026.104727_b0385","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s11011-014-9591-7","article-title":"GLP-1 receptor agonist liraglutide reverses long-term atypical antipsychotic treatment associated behavioral depression and metabolic abnormalities in rats","volume":"30","author":"Sharma","year":"2014","journal-title":"Metab Brain Dis"},{"key":"10.1016\/j.drudis.2026.104727_b0390","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s11481-024-10142-w","article-title":"Semaglutide attenuates anxious and depressive-like behaviors and reverses the cognitive impairment in a type 2 diabetes mellitus mouse model via the microbiota-gut-brain axis","volume":"19","author":"de Paiva","year":"2024","journal-title":"J Neuroimmune Pharmacol"},{"key":"10.1016\/j.drudis.2026.104727_b0395","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.brainres.2018.04.031","article-title":"Liraglutide attenuates the depressive- and anxiety-like behaviour in the corticosterone induced depression model via improving hippocampal neural plasticity","volume":"1694","author":"Weina","year":"2018","journal-title":"Brain Res"},{"key":"10.1016\/j.drudis.2026.104727_b0400","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jad.2022.12.089","article-title":"Effects of liraglutide on depressive behavior in a mouse depression model and cognition in the probe trial of Morris water maze test","volume":"324","author":"Seo","year":"2023","journal-title":"J Affect Disord"},{"key":"10.1016\/j.drudis.2026.104727_b0405","doi-asserted-by":"crossref","DOI":"10.1111\/jcmm.70630","article-title":"Exploring the effect and mechanism of liraglutide in treating depression based on network pharmacology and experimental analysis","volume":"29","author":"Sun","year":"2025","journal-title":"J Cell Mol Med"},{"key":"10.1016\/j.drudis.2026.104727_b0410","doi-asserted-by":"crossref","first-page":"e3448","DOI":"10.1002\/brb3.3448","article-title":"Dulaglutide treatment reverses depression-like behavior and hippocampal metabolomic homeostasis in mice exposed to chronic mild stress","volume":"14","author":"Jin","year":"2024","journal-title":"Brain Behav"},{"key":"10.1016\/j.drudis.2026.104727_b0415","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2023.121546","article-title":"Dulaglutide impedes depressive-like behavior persuaded by chronic social defeat stress model in male C57BL\/6 mice: implications on GLP-1R and cAMP\/PKA signaling pathway in the hippocampus","volume":"320","author":"Darwish","year":"2023","journal-title":"Life Sci"},{"key":"10.1016\/j.drudis.2026.104727_b0420","doi-asserted-by":"crossref","unstructured":"Zhang S, et al. Dulaglutide ameliorates chronic stress-induced cognitive impairment via regulating gut microbiota and serum metabolites in mice. Published online. https:\/\/doi.org\/10.21203\/rs.3.rs-5279490\/v1.","DOI":"10.21203\/rs.3.rs-5279490\/v1"},{"key":"10.1016\/j.drudis.2026.104727_b0425","doi-asserted-by":"crossref","unstructured":"Maradia J, Joshi SS, Koli P, Radhakrishnan M, Athavale C. Evaluating the antidepressant effects of tirzepatide on unpredictable chronic mild stress-induced depression in Swiss Albino mice. Tzu Chi Med J. Published online. https:\/\/doi.org\/10.4103\/tcmj.TCMJ-D-25-00078.","DOI":"10.4103\/tcmj.TCMJ-D-25-00078"},{"key":"10.1016\/j.drudis.2026.104727_b0430","doi-asserted-by":"crossref","first-page":"3898","DOI":"10.18632\/aging.202358","article-title":"Intranasal treatment of lixisenatide attenuated emotional and olfactory symptoms via CREB-mediated adult neurogenesis in mouse depression model","volume":"13","author":"Ren","year":"2021","journal-title":"Aging"},{"key":"10.1016\/j.drudis.2026.104727_b0435","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1002\/oby.21387","article-title":"Effects of liraglutide in hypothalamic arcuate nucleus of obese mice","volume":"24","author":"Barreto-Vianna","year":"2016","journal-title":"Obesity"},{"key":"10.1016\/j.drudis.2026.104727_b0440","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.jnutbio.2018.07.009","article-title":"Liraglutide modulates gut microbiota and reduces NAFLD in obese mice","volume":"62","author":"Moreira","year":"2018","journal-title":"J Nutr Biochem"},{"key":"10.1016\/j.drudis.2026.104727_b0445","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2023.122585","article-title":"Fat fighting liraglutide based nano-formulation to reverse obesity: design, development and animal trials","volume":"634","author":"Jakhar","year":"2023","journal-title":"Int J Pharm"},{"key":"10.1016\/j.drudis.2026.104727_b0450","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1507\/endocrj.EJ21-0802","article-title":"A novel anti-obesity mechanism for liraglutide by improving adipose tissue leptin resistance in high-fat diet-fed obese mice","volume":"69","author":"Lyu","year":"2022","journal-title":"Endocr J"},{"key":"10.1016\/j.drudis.2026.104727_b0455","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1515\/hmbci-2013-0069","article-title":"Circulating and adipose tissue matrix metalloproteinases in cardiometabolic risk environments: pathophysiological aspects","volume":"17","author":"Berg","year":"2014","journal-title":"Horm Mol Biol Clin Investig"},{"key":"10.1016\/j.drudis.2026.104727_b0460","article-title":"Effects of semaglutide on metabolism and gut microbiota in high-fat diet-induced obese mice","volume":"16","author":"Sun","year":"2025","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.drudis.2026.104727_b0465","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.133429","article-title":"Semaglutide lowers body weight in rodents via distributed neural pathways","volume":"5","author":"Gabery","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.drudis.2026.104727_b0470","first-page":"1","article-title":"Efficacy of GLP-1 analog peptides, semaglutide, tirzepatide, and retatrutide on MC4R deficient obesity and their comparison","author":"Hitaka","year":"2026","journal-title":"Int J Obesity"},{"key":"10.1016\/j.drudis.2026.104727_b0475","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-75965-2","article-title":"The risk of depression, anxiety, and suicidal behavior in patients with obesity on glucagon like peptide-1 receptor agonist therapy","volume":"14","author":"Kornelius","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.drudis.2026.104727_b0480","unstructured":"GLP-1 RAs: warnings aligned over potential risk of suicidal thoughts or behaviours. Therapeutic Goods Administration (TGA). Accessed 3 Jun 2026. https:\/\/www.tga.gov.au\/news\/safety-updates\/glp-1-ras-warnings-aligned-over-potential-risk-suicidal-thoughts-or-behaviours."},{"key":"10.1016\/j.drudis.2026.104727_b0485","first-page":"388","article-title":"Glucagon-like peptide-1 receptor agonists and risk of suicidality among patients with type 2 diabetes: active comparator, new user cohort study","author":"Shapiro","year":"2025","journal-title":"BMJ"},{"key":"10.1016\/j.drudis.2026.104727_b0490","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1001\/jamapsychiatry.2025.0679","article-title":"Glucagon-like peptide 1 receptor agonists and mental health: a systematic review and meta-analysis","volume":"82","author":"Pierret","year":"2025","journal-title":"JAMA Psychiat"},{"key":"10.1016\/j.drudis.2026.104727_b0495","doi-asserted-by":"crossref","first-page":"3","DOI":"10.4103\/hm.HM-D-25-00125","article-title":"Changes in psychiatric symptoms, eating disorder behaviors, and health behaviors following six months of GLP-1 treatment for obesity: a pre-to-post-treatment study","volume":"10","author":"Rutledge","year":"2026","journal-title":"Heart Mind"},{"key":"10.1016\/j.drudis.2026.104727_b0500","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2025.1629157","article-title":"Effect of liraglutide on depressive symptoms in overweight or obese patients with type 2 diabetes: protocol for a pilot randomized controlled trial","volume":"16","author":"Fang","year":"2026","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.drudis.2026.104727_b0505","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1080\/09513590.2018.1505848","article-title":"The effects of treatment with liraglutide on quality of life and depression in young obese women with PCOS and controls","volume":"35","author":"Kahal","year":"2019","journal-title":"Gynecol Endocrinol"},{"key":"10.1016\/j.drudis.2026.104727_b0510","article-title":"Feasibility, adherence and efficacy of liraglutide treatment in a sample of individuals with mood disorders and obesity","volume":"10","author":"Cuomo","year":"2019","journal-title":"Front Psychiatry"},{"key":"10.1016\/j.drudis.2026.104727_b0515","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1097\/JCP.0000000000001409","article-title":"Effect of exenatide use on cognitive and affective functioning in obese patients with type 2 diabetes mellitus: exenatide use mediates depressive scores through increased perceived stress levels","volume":"41","author":"Eren-Yazicioglu","year":"2021","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.drudis.2026.104727_b0520","unstructured":"Pardossi S, Pinzi M, Grazi I, Rescalli MB, Cuomo A. Beyond Weight Loss: Tirzepatide and Eating Behaviors in Patients with Bipolar Disorder and Obesity. East West Journal of Psychiatry and Mental Health Patients with Bipolar Disorder and Obesity East West Journal of Psychiatry and Mental Health. 2025. Accessed 18 Mar 2026. https:\/\/www.sciltp.com\/journals\/ewjpmh."},{"key":"10.1016\/j.drudis.2026.104727_b0525","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.pcd.2024.05.005","article-title":"Glucagon-like peptide receptor agonists and risk for depression","volume":"18","author":"Tagliapietra","year":"2024","journal-title":"Prim Care Diabetes"},{"key":"10.1016\/j.drudis.2026.104727_b0530","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.clnu.2025.06.011","article-title":"Psychiatric and psychological adverse effects associated with dulaglutide, semaglutide, and liraglutide: a vigibase study","volume":"51","author":"Nishida","year":"2025","journal-title":"Clin Nutr"},{"key":"10.1016\/j.drudis.2026.104727_b0535","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.jad.2016.09.056","article-title":"Liraglutide promotes improvements in objective measures of cognitive dysfunction in individuals with mood disorders: a pilot, open-label study","volume":"207","author":"Mansur","year":"2017","journal-title":"J Affect Disord"},{"key":"10.1016\/j.drudis.2026.104727_b0540","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1111\/dom.14880","article-title":"Factors associated with successful weight loss after liraglutide treatment for obesity","volume":"25","author":"Sannaa","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.drudis.2026.104727_b0545","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1916038","article-title":"A randomized, controlled trial of liraglutide for adolescents with obesity","volume":"382","author":"Kelly","year":"2020","journal-title":"N Eng J Med"},{"key":"10.1016\/j.drudis.2026.104727_b0550","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/S0140-6736(18)31773-2","article-title":"Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial","volume":"392","author":"O\u2019Neil","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.drudis.2026.104727_b0555","doi-asserted-by":"crossref","unstructured":"FDA \u201cevaluating regulatory action\u201d over link between GLP-1 receptor agonists and suicidal thoughts. Pharmaceutical J. Published online 8 Jan 2024. https:\/\/doi.org\/10.1211\/PJ.2024.1.208135.","DOI":"10.1211\/PJ.2024.1.208135"},{"key":"10.1016\/j.drudis.2026.104727_b0560","unstructured":"Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 8-11 April 2024. European Medicines Agency (EMA). Accessed 3 Jun 2026. https:\/\/www.ema.europa.eu\/en\/news\/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-8-11-april-2024."},{"key":"10.1016\/j.drudis.2026.104727_b0565","doi-asserted-by":"crossref","unstructured":"Brown SL, Bleich A, Van Praag HM. The Monoamine Hypothesis of Depression: The Case for Serotonin. The Role of Serotonin in Psychiatric Disorders. Published online. 2023:91\u2013128. https:\/\/doi.org\/10.4324\/9781315825861-5\/MONOAMINE-HYPOTHESIS-DEPRESSION-SERENA-LYNN-BROWN-AVRAHAM-BLEICH-HERMAN-VAN-PRAAG.","DOI":"10.4324\/9781315825861-5"},{"key":"10.1016\/j.drudis.2026.104727_b0570","doi-asserted-by":"crossref","first-page":"802","DOI":"10.4093\/dmj.2020.0258","article-title":"Comprehensive review of current and upcoming anti-obesity drugs","volume":"44","author":"Son","year":"2020","journal-title":"Diabetes Metab J"},{"key":"10.1016\/j.drudis.2026.104727_b0575","first-page":"63","article-title":"Muscle loss and GLP-1R agonists use","author":"Rossi","year":"2026","journal-title":"Acta Diabetol"},{"key":"10.1016\/j.drudis.2026.104727_b0580","article-title":"GLP-1RAs caused gastrointestinal adverse reactions of drug withdrawal: a system review and network meta-analysis","volume":"14","author":"Zhang","year":"2023","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.drudis.2026.104727_b0585","doi-asserted-by":"crossref","unstructured":"Wu TE, Chen HS. Ocular complications from glucagon-like peptide-1 receptor agonists: Clinical evidence, potential mechanisms, and clinical recommendations. J Chin Med Assoc. Published online 2026. https:\/\/doi.org\/10.1097\/JCMA.0000000000001370.","DOI":"10.1097\/JCMA.0000000000001370"},{"key":"10.1016\/j.drudis.2026.104727_b0590","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/j.survophthal.2023.07.002","article-title":"GLP-1 receptor agonists and diabetic retinopathy: a meta-analysis of randomized clinical trials","volume":"68","author":"Kapoor","year":"2023","journal-title":"Surv Ophthalmol"},{"key":"10.1016\/j.drudis.2026.104727_b0595","first-page":"392","article-title":"Weight regain after cessation of medication for weight management: systematic review and meta-analysis","author":"West","year":"2026","journal-title":"BMJ"}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644626001327?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644626001327?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T20:39:59Z","timestamp":1789504799000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359644626001327"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":119,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S1359644626001327"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2026.104727","relation":{},"ISSN":["1359-6446"],"issn-type":[{"value":"1359-6446","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting the GLP-1 receptor pathways for dual management of obesity and depression","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2026.104727","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104727"}}